Sichuan Goldstone Asia Pharmaceutical Inc.
Shenzhen Stock ExchangeTotal Valuation
Sichuan Goldstone Asia Pharmaceutical Inc. carries a market capitalization of 4.65B, placing it among publicly traded companies globally. Its enterprise value stands at 3.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.65B |
| Enterprise Value | 3.59B |
Share Statistics
Sichuan Goldstone Asia Pharmaceutical Inc. currently has 401.74M shares outstanding.
| Shares Outstanding | 401.74M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Sichuan Goldstone Asia Pharmaceutical Inc. trades at a trailing price-to-earnings ratio of 32.68. The price-to-sales ratio is 3.61, and the price-to-book ratio stands at 6.17.
| PE Ratio | 32.68 |
| PS Ratio | 3.61 |
| PB Ratio | 6.17 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | 40.63 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Sichuan Goldstone Asia Pharmaceutical Inc. trades at an EV/EBITDA multiple of 22.89 and an EV/FCF ratio of 37.29. The EV/Sales ratio of 3.35 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.89 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.35 |
| EV / EBITDA | 22.89 |
| EV / EBIT | 22.89 |
| EV / FCF | 37.29 |
Financial Position
Sichuan Goldstone Asia Pharmaceutical Inc. maintains a current ratio of 2.42, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.31, indicating elevated leverage, while an interest coverage ratio of 122.22 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.42 |
| Quick Ratio | 1.08 |
| Debt / Equity | 5.31 |
| Debt / EBITDA | 0.85 |
| Interest Coverage | 122.22 |
Financial Efficiency
Sichuan Goldstone Asia Pharmaceutical Inc. posts a return on equity of 20.20 and a return on invested capital of 5.08.
| Return on Equity (ROE) | 20.20 |
| Return on Assets (ROA) | 4.08 |
| Return on Invested Capital (ROIC) | 5.08 |
| Return on Capital Employed (ROCE) | 17.84 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.12 |
Taxes
Over the trailing twelve months, Sichuan Goldstone Asia Pharmaceutical Inc. has paid 23.82M in income taxes, reflecting an effective tax rate of 17.17.
| Income Tax | 23.82M |
| Effective Tax Rate | 17.17 |
Stock Price Statistics
Sichuan Goldstone Asia Pharmaceutical Inc.'s stock has gained approximately 19.77226% over the past 52 weeks. The 50-day moving average sits at 10.46, while the 200-day moving average is 10.64.
| Beta (5Y) | N/A |
| 52-Week Price Change | 19.77226% |
| 50-Day Moving Average | 10.46 |
| 200-Day Moving Average | 10.64 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Sichuan Goldstone Asia Pharmaceutical Inc. generated 1.07B in revenue and converted that into 118.30M in net income, yielding earnings per share of 0.29. EBITDA reached 156.74M, while operating income came in at 156.74M.
| Revenue | 1.07B |
| Gross Profit | 616.07M |
| Operating Income | 156.74M |
| Pretax Income | 138.75M |
| Net Income | 118.30M |
| EBITDA | 156.74M |
| EBIT | 156.74M |
| Earnings Per Share (EPS) | 0.29 |
Balance Sheet
Sichuan Goldstone Asia Pharmaceutical Inc. holds 432.88M in cash and equivalents against 133.04M in total debt, resulting in a net debt position of -276.71M. Total book value stands at 626.95M, with working capital of 568.90M providing operational flexibility.
| Cash & Cash Equivalents | 432.88M |
| Total Debt | 133.04M |
| Net Debt | -276.71M |
| Equity (Book Value) | 626.95M |
| Book Value Per Share | 1.56 |
| Working Capital | 568.90M |
Cash Flow
After subtracting -95.14M in capital expenditures, free cash flow totaled -95.14M - equivalent to -0.24 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -95.14M |
| Free Cash Flow | -95.14M |
| FCF Per Share | -0.24 |
Margins
Sichuan Goldstone Asia Pharmaceutical Inc. operates with a gross margin of 57.47, reflecting its pricing power and cost economics. The operating margin of 14.62 and net profit margin of 11.04 provide insight into operational efficiency.
| Gross Margin | 57.47 |
| Operating Margin | 14.62 |
| Pretax Margin | 12.94 |
| Profit Margin | 11.04 |
| EBITDA Margin | 14.62 |
Dividends & Yields
The company's payout ratio of 25.85 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.07 |
| Dividend Yield | N/A |
| Payout Ratio | 25.85 |
| Shareholder Yield | 1.61 |
| FCF Yield | 2.46 |
Stock Splits
Sichuan Goldstone Asia Pharmaceutical Inc.'s most recent stock split took place on October 12, 2018 with a 5:9 split ratio.
| Last Split Date | 10/12/2018 |
| Split Ratio | 5:9 |
Scores
Sichuan Goldstone Asia Pharmaceutical Inc. posts an Altman Z-Score of 5.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.75 |